BCM
NGNE icon

BML Capital Management’s Neurogene NGNE Stock Holding History

BML Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,666
Closed -$478K – 34
2023
Q4 		$478K Hold
24,666
– – 0.36% 30
2023
Q3 		$390K Buy
24,666
+23,479
+1,978% +$347K 0.36% 23
2023
Q2 		$19.7K Hold
1,187
– – 0.02% 31
2023
Q1 		$16.6K Buy
+1,187
New +$13.9K 0.01% 31

Other funds holding NGNE

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BML Capital Management's NGNE Position: Q1 2024 in Review

BML Capital Management sold out of Neurogene (NGNE) in Q1 2024, closing a stake of 24,666 shares — an estimated $478K sold.

BML Capital Management first reported a position in NGNE in Q1 2023 and held it in 4 quarters. The position peaked at $478K in Q4 2023. 60 funds tracked by Wall St. Rank hold NGNE as of Q1 2024.

  • BML Capital Management reported no remaining Neurogene position as of Q1 2024 after selling out during the quarter.
  • BML Capital Management sold 24,666 Neurogene shares in Q1 2024, an estimated $478K.
  • BML Capital Management first reported a position in Neurogene in Q1 2023 and held it in 4 quarters.
  • BML Capital Management's Neurogene position peaked at $478K in Q4 2023.
  • 60 funds tracked by Wall St. Rank held Neurogene as of Q1 2024.

Based on BML Capital Management's 13F filing for Q1 2024, filed 23 Apr 2024.